Medtech Orthofix Medical Q2's sales growth beat expectations

Orthofix Medical

05/08/2025 12:45

Overview

Orthofix Medical Q2 2025 net sales rise 2.3%, beating analyst expectations, per LSEG data

Adjusted EBITDA for Q2 2025 beats consensus, reflecting operational improvements

Co launched TrueLok Elevate TBT System and Reef L Interbody System

Outlook

Orthofix reaffirms full-year 2025 net sales guidance of $808 mln to $816 mln

Company expects 2025 adjusted EBITDA between $82 mln and $86 mln

Orthofix anticipates positive free cash flow for full-year 2025

Result Drivers

U.S. SPINE FIXATION - Net sales grew 5% with procedure volume up 7%, driving revenue growth

BONE GROWTH THERAPIES - Achieved 6% net sales growth, with a 7% increase in Fracture sales

NEW PRODUCT LAUNCHES - Global launch of TrueLok Elevate TBT System and U.S. launch of Reef L Interbody System contributed to sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$203.10 mln
$196.90 mln (5 Analysts)
Q2 Adjusted EBITDA
Beat
$20.60 mln
$17.80 mln (5 Analysts)
Q2 Gross Margin
68.7%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Orthofix Medical Inc is $22.00, about 50.7% above its August 4 closing price of $10.85

The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 53 three months ago

Press Release: ID:nBw2CFHSga

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)